1. US Cancer Incidence & Prevalence

  1.1 Leading Cancer Incidence

  1.2 Incidence by State

  1.3 Incidence by Gender

  1.4 Incidence by Age Group

2. US Cancer Vaccine Market Outlook

  2.1 Cancer Vaccine Market Overview

  2.2 Therapeutic & Prophylactic Vaccines Market

  2.3 Cancer Vaccine Pricing & Reimbursement Policy

  2.4 Cancer Vaccine with Orphan Status

  2.5 Cancer Research Funding & Grants

3. US Cancer Vaccine Market Dynamics

  3.1 Favorable Market Drivers

  3.2 Challenges to be Resolved

  3.3 Future Growth Opportunities

4. US Cancer Vaccine Pipeline by Indication

  4.1 Breast Cancer

  4.2 Bladder Cancer

  4.3 Colorectal Cancer

  4.4 Endometrial Cancer

  4.5 Renal Cancer

  4.6 Leukaemia

  4.7 Lung Cancer

  4.8 Skin Cancer

  4.9 Non-Hodgkin Lymphoma

  4.10 Pancreatic Cancer

5. US Cancer Vaccine Pipeline by Clinical Phase

  5.1 In Development Phase: Research till Phase III

  5.2 Marketed Cancer Vaccines

6. US Cancer Vaccine Market Regulations

  6.1 Considerations for Both Early and Late Phase Clinical Trials

     6.1.1 Patient Population

     6.1.2 Monitoring The Immune Response

     6.1.3 Biomarkers As Evidence Of Efficacy

     6.1.4 Adjuvants Used To Stimulate Immune Response

     6.1.5 Multi-Antigen Vaccines

     6.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines

    6.1.7 Concomitant And Subsequent Therapies

  6.2 Considerations for Early Phase Clinical Trials

     6.2.1 Starting Dose And Dosing Schedule

     6.2.2 Booster And Maintenance Therapy

     6.2.3 Dose Escalation

     6.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development

  6.3 Considerations For Late Phase Clinical Trials

     6.3.1 Safety Profile From Early Phase Clinical Trials

     6.3.2 Endpoints

     6.3.3 Statistical Issues

     6.3.4 Control Issues

     6.3.5 Delayed Vaccine Effect

     6.3.6 Autologous Vaccine Trials

    6.3.7 Accelerated Approval Regulations

7. Competitive Landscape: Business Overview & Vaccine Pipeline

  7.1 Merck & Co.

  7.2 GSK

  7.3 Dendreon

  7.4 Aduro BioTech

  7.5 Antigen Express

  7.6 Bavarian Nordic

  7.7 Celldex Therapeutics

  7.8 Oxford BioMedica

  7.9 Galena Biopharma

Figure 2-1: US Cancer Vaccine Market (US$ Billion), 2012-2018

Figure 2-2: US Share in Global Cancer Vaccines Market (%), 2013 & 2018

Figure 2-3: US Vaccine Markey by Therapeutic & Prophylactic Vaccines, 2012 & 2018

Figure 2-4: US Prophylactic Cancer Vaccines Market, (US$ Billion), 2012-2018

Figure 2-5: US Therapeutic Cancer Vaccines Market, (US$ Billion), 2012-2018

Figure 4-1: US Cancer Vaccine Pipeline by Indication (%)

Figure 4-2: US Cancer Vaccine Pipeline by Indication (Number of Vaccines)

Figure 4-3: US Breast Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-4: US Bladder Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-5: US Colorectal Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-6: US Endometrial Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-7: US Renal Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-8: US Leukemia Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-9: US Lung Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-10: US Skin Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-11: US Non-Hodgkin Lymphoma Vaccine Pipeline by Phase (Number of Vaccines)

Figure 4-12: US Pancreatic Cancer Vaccine Pipeline by Phase (Number of Vaccines)

Figure 5-1: US Cancer Vaccine Pipeline by Clinical Phase (%)

Figure 5-2: US Cancer Vaccine Pipeline by Clinical Phase (Number of Trials)

List of Tables

Table 1-1: Estimated Number of New Cases for Selected Cancers by State, US, 2013

Table 1-2: Estimated Number of Deaths for Selected Cancers by State, US, 2013

Table 1-3: Estimated Number of New Cancer Cases and Deaths by Gender, US, 2013

Table 1-4: Estimated New Cancer Cases by Age (years), 2013

Table 1-5: Estimated Cancer Deaths by Age (years), 2013

Table 2-1: US Orphan Designated Cancer Vaccines

Table 2-2: Spending on Cancer Research (US$ Million), 2010-2012

Table 2-3: Grants for Cancer Research (US$), 2013

Table 2-4: Grants for Cancer Research by States (US$), 2013

Table 2-5: Cancer Funding by Area of Research (US$)

Table 5-1: Marketed Cancer Vaccines: Indication & Brand Name

Table 7-1: Merck Cancer Vaccine Pipeline

Table 7-2: GSK Cancer Vaccine Pipeline

Table 7-3: Dendreon Corporation Cancer Vaccine Pipeline

Table 7-4: Aduro BioTech Cancer Vaccine Pipeline

Table 7-5: Aduro BioTech Cancer Immunotherapies

Table 7-6: Antigen Express Cancer Vaccine Pipeline

Table 7-7: Bavarian Nordic Cancer Vaccine Pipeline

Table 7-8: Celldex Therapeutics  Cancer Vaccine Pipeline

Table 7-9: Oxford BioMedica  Cancer Vaccine Pipeline

Table 7-10: Galena Biopharma  Cancer Vaccine Pipeline